ArticlePrehospital emergency care2026
A 'Target Trial Emulation' of Prehospital Sublingual Nitroglycerin Administration for Suspected Acute Coronary Syndrome.
Article in Prehospital emergency care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesPrehospital clinicians administer sublingual nitroglycerin to hundreds of thousands of patients per year in the United States for suspected acute coronary syndrome (ACS), but the effects of this intervention have not been thoroughly studied. We aimed to estimate the association between nitroglycerin administration and prehospital outcomes using a nationwide dataset.
methodsWe evaluated all patients in the ESO Data Collaborative 2023 annual dataset with an EMS clinician primary impression that suggested chest pain, ACS, or a myocardial infarction who received 324 or 325 milligrams of aspirin from emergency medical services (EMS) clinicians following a 9-1-1 call for inclusion. We excluded patients who were <50 years of age, had a pre-aspirin systolic blood pressure (SBP) <120 mmHg or no pre-aspirin SBP and heart rate documented, a pre-aspirin SpO2 < 90%, or pre-aspirin bronchodilator administration. We classified patients as receiving nitroglycerin if a dose was administered within 10 minutes after aspirin administration. To address both confounding and immortal time bias, we used clone-censor weighting to compare these groups using a composite outcome comprised of prehospital CPR, defibrillation, cardioversion, antiarrhythmic administration, or transcutaneous pacing. Our models included age, sex, race, initial pain score, minimum pre-ASA SBP, maximum pre-ASA heart rate, and prehospital documentation of a suspected ST-elevation myocardial infarction (STEMI). We reported all results as effect sizes with 95% confidence intervals at the 50
resultsWe analyzed 70,890 patients (34,887 (49%) nitroglycerin) from 2,119 EMS agencies. Overall, 139 (0.2%) patients experienced our composite outcome. Nitroglycerin administration was not associated with a significant decrease in the composite outcome at any timepoint following administration of aspirin overall (17 min: -0.02% (-0.08, +0.05); 26 min: -0.05% (-0.15, +0.06); 35 min: -0.10% (-0.30, +0.10)) or among the subgroup of patients with suspected STEMI.
conclusionsNitroglycerin administration in the setting of suspected ACS was not associated with a reduction in our composite outcome in the prehospital setting. These analyses were limited by the low prevalence of our outcome and the retrospective, observational nature of these data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.